Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

73.33 +0.91 (+1.26%)
Streaming Delayed Price Updated: 11:17 AM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 114,933
Open 72.94
Bid (Size) 73.15 (4)
Ask (Size) 73.48 (4)
Prev. Close 72.42
Today's Range 72.23 - 73.42
52wk Range 37.82 - 74.00
Shares Outstanding 60,789,712
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga

Performance

YTD
+69.35%
+69.35%
1 Month
+24.86%
+24.86%
3 Month
+46.51%
+46.51%
6 Month
+22.16%
+22.16%
1 Year
+51.16%
+51.16%

More News

Read More
Why Blueprint Medicines Stock Soared Today
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Blueprint Medicines Corp. (NASDAQ: BPMC) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Blueprint Medicines's Earnings: A Preview
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
What 15 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
Why Shares of Blueprint Medicines Are Falling Wednesday
Via The Motley Fool
A Preview Of Blueprint Medicines's Earnings
Via Benzinga
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales Predictions
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
What Will AbbVie Buy Next?
Via The Motley Fool
Analyst Expectations for Blueprint Medicines's Future
Via Benzinga
IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
3 Biotech Stocks Using AI to Change Healthcare Forever
Via InvestorPlace
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
ETF Returns: Mid-Cap Winners And Losers
Via Benzinga
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
Via InvestorPlace
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
EPAM Systems, Amyris, Blueprint Medicines And Other Big Stocks Moving Lower On Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 5, 2023
Via Benzinga
US Stocks Mixed; SAIC Posts Upbeat Results
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.